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Abstract
Activated microglia exerts both beneficial and deleterious effects on neurons, but the signaling mechanism
controlling these distinct responses remain unclear. We demonstrated that treatment of microglial cultures with the
PAR-2 agonist, 2-Furoyl-LIGRLO-NH2, evoked early transient release of BDNF, while sustained PAR-2 stimulation
evoked the delayed release of inflammatory cytokines (IL-1β and TNF-α) and nitric oxide. Culture medium harvested
during the early phase (at 1 h) of microglial activation induced by 2-Furoyl-LIGRLO-NH2 (microglial conditioned
medium, MCM) had no deleterious effects on cultured neurons, while MCM harvested during the late phase
(at 72 h) promoted DNA fragmentation and apoptosis as indicated by TUNEL and annexin/PI staining. Blockade of
PAR-1 during the early phase of PAR-2 stimulation enhanced BDNF release (by 11%, small but significant) while a
PAR-1 agonist added during the late phase (24 h after 2-Furoyl-LIGRLO-NH2 addition) suppressed the release of
cytokines and NO. The neuroprotective and neurotoxic effects of activated microglial exhibit distinct temporal
profiles that are regulated by PAR-1 and PAR-2 stimulation. It may be possible to facilitate neuronal recovery and
repair by appropriately timed stimulation and inhibition of microglial PAR-1 and PAR-2 receptors.
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Background
Microglias are the major resident immunocompetent
cells in the central nervous system (CNS). Microglia acti-
vation in response to trauma, metabolic insult, infection,
or neurodegenerative processes can both enhance neuro-
protection and contribute to neuropathogology [1]. In-
deed, activated microglia are part of an endogenous
system promoting restoration of endangered CNS ele-
ments [2,3], while excessive and sustained stimulation of
these cells contributes to neuropathology by causing the
release of inflammatory mediators and neurotoxins [4-6].
The development of treatment strategies aimed at opti-
mizing the protective actions and minimizing the neuro-
toxic effects of activated microglia remains a substantial
clinical challenge.
Protease-activated receptors (PARs) are a unique family
of four G protein-coupled receptors (PAR-1, -2, -3, and −4)
[7]; PAR-1, PAR-3, and PAR-4 are activated by thrombin,
whereas PAR-2 is activated by trypsin and tryptase [7]. All
members are widely expressed in the CNS by neurons,
microglia, astrocytes, and oligodendrocytes, and are pos-
sible therapeutic targets for the treatment of neurodegen-
erative disorders [8-12]. Under pathological conditions,
PARs have been shown to mediate either neuronal death
or survival. Stimulation of neuronal PAR-2 protected
human neurons against Aβ in vitro [13]. In contrast, acti-
vation of microglial PAR-2 receptors promoted the secre-
tion of neurotoxic factors like nitrite, reactive oxygen
species (ROS), and TNF-α, and the conditioned media
from microglia induced cell death in rat primary neuronal
cultures [13,14]. It is known that activation of microglial
PAR-2 promotes the expression of the ATP-gated ion
channel P2X4R, which in turn can trigger the release of
neuroprotective brain-derived neurotrophic factor (BDNF)
[15-17]. Neurotrophic factors like BDNF mediate axon
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guidance during neural development and can enhance
axonal growth following injury [18].
Whether activation of PAR-2 in microglia is detrimental
or beneficial to neurons remains equivocal. Watanabe, et
al. found that microglia were neuroprotective only during
the early phase of activation and that this effect disap-
peared by the late phase [19]. The mechanisms for this
phenotypic transition are not known, but circumstantial
evidence implicates PAR-1 and PAR-2 receptors. There is
solid evidence that PAR-1 and PAR-2 act as co-factors and
heterodimerization partners during signal transduction.
Kaneider and coworkers demonstrated that PAR-1
switches from being a vascular disruptive to a vascular pro-
tective receptor during the progression of sepsis in mice
and that this functional transition was dependent on PAR-
2 [20]. Clinical findings also demonstrated that patients
with diarrhea-predominant irritable bowel syndrome
exhibited changes in PAR-1/PAR-2 expression ratio in the
colon [21].
We hypothesized that the balance between PAR-1 and
PAR-2 activation in microglia may mediate the functional
transition from a neuroprotective to neurotoxic phenotype.
To clarify the roles of PAR-1 and PAR-2 on microglial
function, we examined the time-dependent changes in
neurotrophic and inflammatory responses following activa-
tion by the PAR-2 agonist.
Materials and methods
Animals
Male and female Sprague Dawley (SD) rat pups from 1 to
3 day-old and E16-17 fetal SD rat embryos were obtained
from the SLAC laboratory animal center, Shanghai, China.
The treatment of all rats used in this study conformed to
the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health publication number 80–23)
as approved by the Ethics Committee for Animals of the
Second Military Medical University.
Cell cultures and experimental treatments
Microglia was isolated and cultured from 1 to 3 day-old
SD rats as previously described [22]. Briefly, the cerebral
cortices were triturated into a single cell suspension in
DMEM-Ham‘s F-12 medium (GIBCO-BRL, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum
(GIBCO-BRL, Grand Island, NY, USA ), 2 mM L-
glutamate, and 1 mM sodium pyruvate. Cells were plated
in 75 cm2 T-flasks and incubated for 14 days. Microglia
were detached from the flasks by mild shaking, and filtered
through a nylon mesh to remove astrocytes and clumped
cells. Purified microglia were plated on 60 or 100 mm
dishes at 0.1-5.0 × 106 cells/dish.
Cultured microglia were incubated with 10 μM of the
PAR-2 agonist 2-Furoyl-LIGRLO-NH2 (Sigma-Aldrich, St.
Louis, MO, USA) to induce activation. Microglia
conditioned medium (MCM) was collected after 0.0, 0.5,
1.0, 2.0, 12.0, 24, or 72.0 h of continuous 2-Furoyl-
LIGRLO-NH2 stimulation. The levels of nitrite, BDNF, IL-
1β, and TNF-α in the MCM were determined by the assays
described in the next subsection. We also examined the
effects of PAR-1 activation and blockade on microglial
neurotrophin release during the early phase of activation
and cytokine release during the late phase of activation. To
examine the effect of PAR-1 activity during the early phase
of activation, microglia were stimulated by 2-Furoyl-
LIGRLO-NH2, 2-Furoyl-LIGRLO-NH2 plus the PAR-1 an-
tagonist SCH79797 (Axon Medchem, Groningen, NL), or
2-Furoyl-LIGRLO-NH2 plus the PAR-1 agonist TFLLR
(Tocris Bioscience, Anonmouth, UK). The three MCM
samples were collected after 1 h of stimulation and the
BDNF concentrations assayed as described in the next sub-
section. To examine the effect of PAR-1 activity on micro-
glial secretion of cytokines and nitric oxide (NO) during
the late phase, microglia were stimulated with 2-Furoyl-
LIGRLO-NH2 for 24 h, followed by addition of SCH79797
or TRLLR. The MCM was collected 48 h after agonist or
antagonist application (or 72 h after the onset of 2-Furoyl-
LIGRLO-NH2 stimulation) and assayed as described
below.
Primary rat neurons were prepared from E16 SD rat
embryos as previously described [23]. Briefly, the cerebral
cortex was dissected and transferred into Ca2+- and Mg2
+-free D-Hank's solution. The dissected tissues were incu-
bated in trypsin solution at 37°C and dissociated by tritur-
ation. The dissociated cells were re-suspended in B27-
supplemented neurobasal medium (Invitrogen, Carlsbad,
CA, USA) and plated onto 60 mm culture dishes. Cultured
cortical neurons were incubated for 10 days at 37°C under
10% CO2 before experiments.
To examine the effects of MCM collected at different
times after the start of PAR-2 stimulation on neuronal via-
bility, cultured neurons were incubated for 48 h in MCM
from unstimulated microglia (control condition), MCM
collected after 1 h of 2-Furoyl-LIGRLO-NH2 stimulation
(1 h MCM or early phase MCM), or MCM collected after
72 h of 2-Furoyl-LIGRLO-NH2 stimulation (72 h MCM or
late phase MCM). The neurotoxicity of these supernatants
was estimated by transferase-mediated dUTP nick-end la-
beling (TUNEL) assay and flow cytometry as described
below.
Transfection and clone selection
The PAR-2 shRNA (r) lentiviral particles were purchased
from Santa Cruz Biotechnology, Inc. Control shRNA lenti-
viral particles were used as controls. The lentiviral parti-
cles were transfected into cells according to the
manufacturer's instructions. Stably transfectant clones
were selected via Puromycin dihydrochloride (Sigma-
Aldrich, St. Louis, MO, USA) selection and were validated
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by quantitative real-time polymerase chain reaction (qRT-
PCR) and immunoblotting.
Realtime PCR
An RNeasy Mini Kit (Qiagen, Shanghai, CHN) was
used to extract RNA from cells. Total RNA (200 ng)
and oligo-dT primers were used to synthesize single-
stranded cDNA using Qiagen’s Omniscript reverse
transcriptase according to the manufacturer’s instruc-
tions. The resulting cDNA was purified and PCR was
set up with an ABI Prism 7900 Sequence Detection
System and SYBR green Master Mix (Applied Biosys-
tems, Carlsbad, CA, USA). The primers used were as
follows: 5’- CGTGCTGCTCGTCGTGCATTATTT-3’
and 5’- TTTCTGGCCTGGTCCCTGAAATCT-3’ for
PAR2, 5’- TTGCTGACAGGATGCAGAAGGAGA -3’
and 5’- ACTCCTGCTTGCTGATCCACATCT -3’ for β-
actin. The relative expression of PAR2 mRNA was calcu-
lated with the 2 to the power of minus Delta Delta CT
(2T
-55C) method, using β-actin mRNA expression level
for normalization.
Western blotting
Cells were homogenized and scraped in lysis buffer
(50 mM Tris_HCl, pH 8.0, 1 mM EDTA, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 29
protease inhibitor mix). Then the samples were centrifuged
and the supernatant was collected. The proteins were sepa-
rated by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE and transferred to polyvinylidene
difluoride (PVDF) membrane, and the specific proteins
were detected by immunoblotting. Primary antibodies
against PAR-2 (sc-13504, Santa Cruz, CA, USA) and β-
actin (sc-81178, Santa Cruz, CA, USA) were used to probe
the blots.
Measurement of nitrite, BDNF, IL-1β, and TNF-α
The levels of BDNF, IL-1β, and TNF-α in culture super-
natant were determined by enzyme-linked immunosorbent
assay (ELISA) with specific reagent kits (R&D Systems,
Inc., USA) following the manufacturer’s instructions. Nitric
oxide production was calculated from the amount of nitrite
detected in the media by the Griess reaction as reported
previously [24]. For statistical analysis, data were obtained
from at least three individual experiments.
Cell viability assay
Cell viability of cultured microglial cells were measured by
quantitative colorimetric assay with 3-(4,5)-dimethylthia-
hiazo(−z-y1)-3,5-di-phenytetrazoliumromide (MTT) (Sigma-
Aldrich, St. Louis, MO, USA). The MTT assay relies pri-
marily the mitochondrial activity of living cells and reflects
the intracellular redox state. Upon termination of the
experiments, the culture media were aspirated and MTT
(final concentration, 1 mg/ml) was added to cells and then
incubated at 37°C for 2 h. The supernatant was aspirated
and dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO,
USA) was added to the wells. Insoluble crystals were dis-
solved by mixing and the plates were read on an absorb-
ance reader, using a test wavelength of 570 nm and a
reference wavelength of 630 nm. Results were expressed as
the percentage (%) of MTT reduction, assuming that the
absorbance of control cells was 100%.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL)
Fragmentation of DNA in early apoptotic neurons was
assayed using a commercially available in situ death detec-
tion kit (product of Roche Diagnostic). Neurons (1×105
cells/ml) were treated as described and fixed for 30 min in
10% neutral buffered-formalin solution at room
temperature. For TUNEL labeling, the in situ cell death de-
tection kit (fluorescein) from Roche Applied Science was
used according to the manufacturer’s instructions. Staining
with 4,6-diamidino-2-phenylindole (DAPI) was performed
using a ready-to-use mounting medium containing DAPI.
Labeled cells were rinsed with phosphate-buffered saline
(PBS) and examined under a confocal microscope with ex-
citation at 488 nm and emission at 525 nm. Percentage of
apoptotic cells was calculated by counting in at least 6 ran-
domly chosen subfields. Results are mean ± standard error
(SE) of counting in three independent experiments.
Measurement of apoptotic cell death by flow cytometry
Rat cultured neurons (5× 105/dish) were treated with
6.84 mM EDTA (Sigma-Aldrich, St. Louis, MO, USA) and
0.05% trypsin (Sigma-Aldrich, St. Louis, MO, USA) for 5
to 7 minutes. The cells were detached by shaking in order
to bring them into suspension. The cells were then har-
vested by centrifuging at 200×g for 5 minutes. The cell
pellet was re-suspended in 100 μl of 1 mg/ml annexin-V-
FITC in HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-
sulphonic acid) buffer with 1.8 mM CaCl2. The suspension
was incubated for 5 to 10 minutes at room temperature in
the dark, followed by addition of 1 ml HEPES containing
10 mg/ml propidium iodide (PI). The fraction of apoptotic
cells was analyzed immediately by flow cytometry (Becton
Dickinson, San Jose, CA).
Statistical analysis
Mean values were calculated from three or more inde-
pendent experiments and are reported as mean ± SE.
Group means were compared by one-way analysis of vari-
ance (ANOVA), followed by post hoc pair-wise compari-
sons using Student-Newman-Keuls tests. A P value< 0.05
was defined as statistically significant.
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Results
The PAR-2 agonist 2-furoyl-LIGRLO-NH2 induced early
release of BDNF and delayed release of proinflammatory
cytokines from rat microglia
To examine the distinct neurotrophic and inflammatory
responses of microglia after PAR-2 stimulation, cultured
microglia were incubated with the PAR-2 agonist 2-Furoyl-
LIGRLO-NH2 (Figure 1). Microglia conditioned medium
(MCM) was collected after 0.0, 0.5, 1.0, 2.0, 12.0, 24.0, and
72.0 h of 2-Furoyl-LIGRLO-NH2 stimulation and the
amount of BDNF, IL-1β, and TNF-α released was mea-
sured by ELISA. The concentration of BDNF rose signifi-
cantly during the first 1 h of 2-Furoyl-LIGRLO-NH2
treatment, but returned to near baseline within 72 h. In
contrast, the concentrations of the proinflammatory factors
IL-1β and TNF-α did not increase until 12 to 24 h after
Figure 1 Release of neurotrophic and proinflammatory factors from PAR-2 activated rat microglia. Cells were treated with 10 μM
2-Furoyl-LIGRLO-NH2 in the presence or absence of PAR-2 shRNA. The concentration of BDNF, IL-1β, TNF-α, and NO in the supernatant were
determined at 0.0, 0.5, 1.0, 2.0, 12.0, 24.0, and 72.0 h after 2-Furoyl-LIGRLO-NH2 application as described previously (A, B, C, D). All values
represent means ± SE. *Significantly different from control group (P< 0.05). qRT-PCR and immunoblot analysis were also shown to verify the
decreased expression of PAR-2 in the PAR-2 shRNA treated rat microglia (E, F).
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the start of 2-Furoyl-LIGRLO-NH2 treatment and
remained elevated for at least 72 h. Similarly, nitrate con-
centration, a proxy for NO release, also rose after about
12 h of 2-Furoyl-LIGRLO-NH2 treatment and continued
to increase for the duration of the measurement period.
Thus, neuroprotective BDNF was released from microglia
during the early phase of the activation response while
proinflammatory cytokines and cytotoxic NO were only
released in response to sustained PAR-2 activation.
When the PAR-2 shRNA expression vector was trans-
fected into the microglia, the expression of PAR-2 was
reduced significantly. In this condition, increased release
of BDNF, cytokine, and NO induced by 2-Furoyl-
LIGRLO-NH2 was inhibited significantly, indicating that
all these secretory responses were mediated by PAR-2
activation.
The MCM from late-phase PAR-2-activated microglial
was neurotoxic
To evaluate the effects of these microglial factors on neur-
onal viability, the media from 2-Furoyl-LIGRLO-NH2-
treated microglia (MCM) was retrieved and used to treat
cultured cortical neurons. Cultured neurons were incu-
bated for 48 h in MCM collected from microglial cultures
after 0, 1, or 72 h of 2-Furoyl-LIGRLO-NH2 stimulation.
Neuronal viability was assessed by the TUNEL assay for
DNA fragmentation associated with activation of apoptotic
signaling cascades (Figure 2). The number of TUNEL-
positive cells was significantly higher in neuronal cultures
incubated in 72 h MCM than in cultures incubated in
media from unstimulated microglia (control MCM), while
the number of TUNEL-positive neurons in cultures incu-
bated with 1 h MCM was not significantly different from
cultures incubated in control MCM. Consistent with the
results presented in Figure 1, the MCM from 2-Furoyl-
LIGRLO-NH2-stimulated microglia only induced apop-
tosis when microglia entered the late phase of the reactive
response associated with the release of inflammatory cyto-
kines and NO.
An annexin V-FITC/PI apoptosis detection kit was used
to quantify the percentage of apoptotic neurons following
MCM treatment. Three populations of neurons were dis-
tinguished by this dual staining method: viable (no stain-
ing), early apoptotic (Annexin V + PI−), and late apoptotic
(Annexin V + PI+). Flow cytometry demonstrated that the
percentage of early apoptotic and late apoptotic neurons
incubated in 72 h MCM was significantly higher than in
cultures treated with 1 h MCM or MCM from untreated
microglial cultures (Figure 3).
Blockade and activation of PAR-1 altered PAR-2-induced
BDNF and cytokine release from microglia
The relative balance of PAR-1 and PAR-2 receptor expres-
sion (or stimulation) appears to mediate the phenotypic
switching of resident immune cells in other tissues. To test
the hypothesis that PAR-1 and PAR-2 can also regulate the
distinct neuroprotective and neurotoxic temporal phases
of microglial activation, we tested the effects of a PAR-1
agonist (TFLLR) and antagonists (SCH79797). MCM was
collected at 0, 1, and 72 h and analyzed for BDNF, IL-1β,
TNF-α, and NO metabolite content. Early blockade of
PAR-1 increased the release of BDNF from microglia. In
contrast, PAR-1 activation at 24 h after 2-Furoyl-LIGRLO
-NH2 stimulation significantly decreased the late phase re-
lease of NO, IL-1β, and TNF-α (Figure 4). These results in-
dicate that PAR-1 and PAR-2 receptors control the
beneficial neurotrophic response and the late phase inflam-
matory cytotoxic response [20].
Since it has been widely reported in the literature that
PAR-1 activation can modify cell proliferation and cell
death, the viability of microglial cells was evaluated using
the MTT test after treatment with the PAR-2 agonist in
combination with PAR-1 agonist or antagonists. PAR2
agonist (2-Furoyl-LIGRLO-NH2), PAR-1 agonist (TFLLR)
and antagonists (SCH79797) did not affect cell viability.
Therefore, the effects of blockade and activation of PAR-1
on 2-Furoyl-LIGRLO-NH2-induced inflammation-related
responses in activated microglia were not the result of the
effects on cell survival.
Discussion
Activated microglia can mediate either neuroprotection or
neurotoxicity in both culture models and in vivo. We have
provided evidence that stimulation of PAR-2 activates the
release of both neurotrophic and inflammatory factors
from microglia, but with distinct temporal profiles. Fur-
thermore, we demonstrated that PAR-1 and PAR-2 can
also act as co-factors to promote the beneficial anti-
inflammatory phenotype during the early phase of micro-
glial activation [20]. These data are consistent with the for-
mation of receptor complexes or co-factoring that occurs
with many members of the PAR family [25].
PAR-2 is activated by trypsin, tryptase and some syn-
thetic peptides, such as 2-Furoyl-LIGRLO-NH2 [26]. As
trypsin and tryptase may also proteolyse other molecules
in cell culture, the agonist peptide 2-Furoyl-LIGRLO-NH2,
which could specifically activate PAR-2, was used in our
study. It has been demonstrated that stimulation of PAR-2
also triggered activation of rat primary microglial cells [14].
Microglial activation triggers the secretion of a variety of
proinflammatory and neurotoxic factors, including NO,
IL-1β, IL-6, and TNF-α, which can damage surrounding
cells [27-29]. Previous studies have demonstrated that
PAR-2 expression in local glial cells was increased in Alz-
heimer’s disease and paralleled upregulation of proinflam-
matory cytokines and chemokines [13]. Activation of
microglial cells by PAR-2 stimulation produced condi-
tioned media that were toxic to cultured rat primary
Chen et al. Journal of Neuroinflammation 2012, 9:142 Page 5 of 10
http://www.jneuroinflammation.com/content/9/1/142
neurons [14]. The neurodegenerative effects of PAR-2
stimulation are mediated by the mitogen-activated protein
kinase (MAPK) pathways, including ERK1/2, c-Jun N-
terminal kinase (JNK), and p38MAPK. However, it is well
known that MAPKs mediate diverse biological processes
and cellular responses, so we investigated the possibility
that PAR-2 could induce the release of either neurotrophic
or inflammatory cytokines depending on stimulus condi-
tions. Indeed, activation of PAR-2 expressed on rat primary
microglial cells triggered the early transient release of
Figure 2 Stage-specific effect of MCM on nuclear DNA fragmentation in rat cortical neurons. Neurons were incubated in unstimulated
MCM (control), MCM at 1 h after 10 μM 2-Furoyl-LIGRLO-NH2 stimulation (early phase) and MCM at 72 h after stimulation (late phase) for 48 h.
Internucleosomal DNA fragmentation was determined by a fluorescent TUNEL assay. Percentage of apoptotic cells was calculated by counting in
at least 6 randomly chosen subfields. Values are means ± SE. *Significantly different from control group, P< 0.05; # No significantly different from
control group, P> 0.05.
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BDNF and the delayed release of inflammatory cytokines
and NO.
Brain-derived neurotrophic factor is a member of the
neurotrophin family of growth factors that enhance axonal
growth following injury and maintain neuronal viability
under a variety of stressful conditions. Thus, PAR-2-
mediated activation of microglia may exert immediate but
transient neuroprotective effects following insult, whereas
sustained activation would lead to a delayed late phase re-
sponse associated with the release of proinflammatory
cytokines that contribute to neuronal cell death. Dual
annexin/PI staining and TUNEL staining demonstrated a
marked increase in apoptotic neurons when treated with
MCM at 72 h after 2-Furoyl-LIGRLO-NH2 stimulation.
This results are consistent with previous reports showing
that the neuroprotective effect of microglia appears only in
the early phase after glutamate treatment (a model of exci-
totoxicity) but disappeared in the late phase [19].
The second question addressed in this study was
whether PAR-1 and PAR-2 stimulation act together to in-
fluence activated microglia phenotype. It is known that
PAR-mediated signal transduction is also modulated by
interactions with other PARs [25]. PAR-3 functions as a
co-factor facilitating thrombin-mediated activation of PAR-
4 [30,31], and PAR-1 and PAR-2 mediate crosstalk between
coagulation and fibrinolysis on tumor cells [32]. In
addition, PAR-1 switched from a vascular disruptive to a
vascular protective receptor during sepsis in mice, a func-
tional transition that was dependent on PAR-2 receptors.
Stimulation of PAR-1 and PAR-2 might confer a beneficial
anti-inflammatory microglial phenotype only within a brief
time window. Greater appreciation of these distinct tem-
poral phases of activation may allow PARs to be exploited
clinically. Indeed, selective activation of PAR-1/PAR-2
complexes was beneficial for the treatment of sepsis at a
specific stage [20], so we surmised that PAR-1 and PAR-2
Figure 3 Stage-specific effect of MCM on apoptotic cell death in rat cortical neurons. Neurons were exposed to unstimulated MCM
(control), MCM at 1 h after 10 μM 2-Furoyl-LIGRLO-NH2 stimulation (early phase) and MCM at 72 h after stimulation (late phase) for 48 h.
The percentage of early apoptotic and late apoptotic cells was determined by fluorescence activated cell sorting (FACS). Data are means ± SE.
*Significant differences from control group, P< 0.05; # No significant difference from control group: P> 0.05.
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Figure 4 Stage-specific effect of a PAR-1 agonist and antagonist on neurotrophic and proinflammatory responses in rat microglia
activated by 2-Furoyl-LIGRLO-NH2. (A) Microglia was stimulated by 2-Furoyl-LIGRLO-NH2 (10 μM), 2-Furoyl-LIGRLO-NH2 plus SCH79797 (1 μM),
or 2-Furoyl-LIGRLO-NH2 (10 μM) plus TFLLR (0.5 μM). The concentration of BDNF in MCM that was collected at 1 h after stimulation was
determined by ELISA. Values are means ± SE. *Significantly different from 2-Furoyl-LIGRLO-NH2 treated group, P< 0.05. (B, C, D) Microglia was
stimulated by 2-Furoyl-LIGRLO-NH2, then SCH79797 or TRLLR was added 24 h later (during the late phase of microglial activation). The
concentration of IL-1β, TNF-α, and NO in MCM collected at 72 h after 2-Furoyl-LIGRLO-NH2 stimulation were determined as described. Values are
means ± SE. *Significantly different from 2-Furoyl-LIGRLO-NH2 treated group: P< 0.05. (E) Cell viability was assessed by MTT assay, and the
percentage of surviving cells compared to control cells. Values are means ± SE. # No significantly different from control group, P> 0.05.
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activation in microglia may exert similar functions. Our
results showed that PAR-1 exerted stage-specific beneficial
and detrimental effects by suppressing PAR-2-stimulated
secretion. PAR-1 stimulation decreased the release of
BDNF during the early phase of the reactive response, sug-
gesting that early PAR-1 receptor activation may inhibit
neuroprotection. Conversely, later PAR-1 stimulation sup-
pressed the release of inflammatory mediators, suggesting
a beneficial anti-inflammatory effect. This may be partly
explained by the fact that activation of PAR-1 induces the
expression of suppressor of cytokine signaling-3 (SOCS-3)
in microglia [33]. Upon injury, up regulated cytokines act
as proinflammatory agents as a part of a defense mechan-
ism, but excessive or prolonged activation could be detri-
mental to the CNS. SOCS-3 is a crucial mediator which
executes tight control of the strength and duration of these
cytokine-triggered signaling pathways. Previous studies
showed that deletion of SOCS3 in adult retinal ganglion
cells promotes robust regeneration of injured optic nerve
axons and up regulates the release of ciliary neurotrophic
factor [34,35]. So, we postulated that during early phase of
injury, transient up regulation of SOCS3, which aims to
protect against further tissue damage by limiting produc-
tion of inflammatory factors might inhibit 2-Furoyl-
LIGRLO-NH2-induced BDNF release in microglial cells.
However, SOCS3 has a short half-life (1 to 2 h) and its sta-
bility can be regulated by other proteins [36]. For these, at
the later stage, the anti-inflammatory effects of SOCS3 are
limited. Thus, at the later stage, activation of SOCS3 would
exert its beneficial effects by limiting inflammation and
suppressing immune responses. Futher, PAR1 which
induces the expression of SOCS3 in microglia, has been
proved to switch from being a detrimental to a benefical
receptor during the progression of sepsis in mice [20]. The
functional interactions between PAR-1 and PAR-2 in
microglia underscore the ubiquity of these receptor com-
plexes or co-factoring that occurs with many members of
the PAR family.
In conclusion, the present study revealed that activa-
tion of microglia by PAR-2 stimulation triggered the se-
quential release of neuroprotective and neurotoxic
factors, with early transient release of BDNF and delayed
sustained release of NO, IL-1β, and TNF-α. Increased
release of NO, IL-1β, and TNF-α at the late phase of
PAR-2 stimulation could mediate apoptotic cell death of
the neuron. Stage-specific blockade or activation of
PAR-1 altered the amounts of neurotrophins and cyto-
kines released in response to PAR-2 stimulation. PAR-1
antagonism increased the release of BDNF at the early
phase (by 11%, small but significant), while PAR-1 agon-
ism reduced the release of proinflammatory mediators
during the late phase. These distinct temporal profiles
could be exploited to develop novel therapeutic strat-
egies for CNS injury.
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